Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 plus chemotherapy for EGFR/ALK/ROS1 positive NSCLC (Apple)
NCT06196814Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Oct 2024
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06196814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196814.